Upgrade to SI Premium - Free Trial

Benchmark Upgrades AbCellera Biologics (ABCL) to Buy

July 7, 2026 6:16 AM
Benchmark analyst Robert Wasserman upgraded AbCellera Biologics (NASDAQ: ABCL) from ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Upgrades